Scribd
Upload
2K views1 page

Pebc Statistics

In a 2-year randomized controlled trial comparing a new drug to a placebo: - 25% of patients who received the new drug achieved the desired clinical outcome, compared to 15% of patients who received the placebo. - The relative risk reduction of the new drug was calculated to be 40%. In a 3-year randomized controlled trial comparing a conventional therapy to a newly discovered drug: - A specific serious side effect occurred in 0.5% of patients receiving conventional therapy and 0.45% of patients receiving the new drug. - Based on these results, the minimum number of patients needed to receive the new drug for 3 years to statistically demonstrate prevention of at least one episode of the side effect is 2000

Uploaded by

George Zachariah
Copyright
© Attribution Non-Commercial (BY-NC)
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOC, PDF, TXT or read online on Scribd
2K views1 page

Pebc Statistics

In a 2-year randomized controlled trial comparing a new drug to a placebo: - 25% of patients who received the new drug achieved the desired clinical outcome, compared to 15% of patients who received the placebo. - The relative risk reduction of the new drug was calculated to be 40%. In a 3-year randomized controlled trial comparing a conventional therapy to a newly discovered drug: - A specific serious side effect occurred in 0.5% of patients receiving conventional therapy and 0.45% of patients receiving the new drug. - Based on these results, the minimum number of patients needed to receive the new drug for 3 years to statistically demonstrate prevention of at least one episode of the side effect is 2000

Uploaded by

George Zachariah
Copyright
© Attribution Non-Commercial (BY-NC)
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOC, PDF, TXT or read online on Scribd

BIOSTATISTICS MCQs

In an adequately powered, randomized controlled trial conducted over 2 years, the desired clinical outcome (i.e. prevention of a serious cardiovascular event) with a new drug is achieved in 25% of the study sample. In the patients who receive a placebo, only 15% obtain the same clinical benefit. The relative risk reduction achieved with the new drug over the study period is: a. 10%. b. 15%. c. 25%. d. 40%. e. 50%. there is a formula to calculate this. RRR = (EER-CER)/EER WHERE, RRR= RELATIVE RISK REDUCTION EER= EXPERIMENTAL EVENT RATE CER= CONTROL EVENT RATE(PLACEBO) RRR = 25-15/25 RRR= 0.4 since they asked for percentile we have to multiplied it with 100. so, FINAL ANSWER IS 0.4*100 = 40% In an adequately powered, randomized controlled trial conducted over 3 years, a specific serious side effect (i.e. reduction in leukocytes) with conventional therapy is seen in 0.5% of the study sample. In patients who receive a newly discovered drug, only 0.45% experience the same side effect. Based on these results, the minimum number of patients that would have to receive the new drug for 3 years to statistically demonstrate the prevention of one episode of this side effect in at least one patient is: a. 15. b. 20. c. 150. d. 200. e. 2000 THERE IS FORMULA FOR THIS ALSO: NNT= 1/ARR*100 WHERE, NNT= NO. NEEDED TO TREAT ARR= ABSOLUTE RISK REUCTION ARR= EER-CER ARR= 0.45-0.5 ARR= 0.05(negative sign means new drug is not more effective than previous one.) NNT= 1/0.05*100 NNT= 2000

You might also like